Phase I Study of AMG 510, a Novel KRASG12C Inhibitor, in Advanced KRASG12C-Positive Solid Tumors

May 31 - June 4, 2019; Chicago, Illinois
AMG 510 showed a tolerable safety profile and preliminary antitumor activity in previously treated patients with KRASG12C-positive tumors, including NSCLC.
Format: Microsoft PowerPoint (.ppt)
File Size: 195 KB
Released: June 5, 2019

Acknowledgements

Provided by the USF Health

Contact Clinical Care Options

For customer support please email: customersupport@clinicaloptions.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

This activity is supported by an educational grant from
Blueprint Medicines

Related Content

Global perspectives of key novel combination studies presented at ASCO 2021 from international experts in solid tumors from Clinical Care Options (CCO)

person default Dirk Arnold, MD, PhD Prof Isabelle Ray-Coquard, MD, PhD Egbert F. Smit, MD, PhD Released: August 5, 2021

Professor Keith M. Kerr on fine points of testing for EGFR exon 20 insertion mutations in management of advanced NSCLC, commentary from Clinical Care Options (CCO)

person default Keith M. Kerr, MB ChB, FRCPath, FRCPE Released: August 5, 2021

Slides from Clinical Care Options (CCO) on biomarker testing to guide targeted therapy for gastrointestinal cancer

Allison M. Cushman-Vokoun, MD, PhD John L. Marshall, MD Released: August 5, 2021

David Planchard, MD, PhD, discusses barriers to osimertinib access worldwide and future directions for the management of advanced EGFR-mutated NSCLC.

David Planchard, MD, PhD Released: July 29, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue